Biopharma companies COVID-19 research involved YTD stock performance March 2020

Year-to-date stock performance of select U.S. biopharmaceutical companies working on COVID-19 treatments or vaccines as of March 11, 2020

YTD stock performance of biopharma companies working on COVID March 2020

Last update:

Mar 13, 2020

Author:

��ƽ�� Research Department

Region:

United States

Survey time period:

From 01/03/2020 to 11/03/2020

Of the U.S. biopharmaceutical companies currently developing treatments or vaccines targeting the COVID-19 infection caused by coronavirus, Vir Biotechnology Inc.'s shares have increased by 279 percent as they are in the midst of preclinical testing monoclonal antibodies as a treatment for this disease. This statistic shows the year-to-date stock performance of select biopharmaceutical companies working on COVID-19 treatments or vaccines in the U.S. as of March 11, 2020.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Year-to-date stock performance of select U.S. biopharmaceutical companies working on COVID-19 treatments or vaccines as of March 11, 2020

Get in touch with us for additional information

��ƽ��